Multinationals Dispute Deposits Demanded By Jiangsu Hospital
This article was originally published in PharmAsia News
A major hospital in China has started asking drug makers to put down cash deposits or face suspension, is it a desperate measure from cash-constrained hospitals or legitimate request based on supply contracts? Legal experts share views on the thorny issue.
You may also be interested in...
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.